Literature DB >> 16493427

Immune regulation by SLAM family receptors and SAP-related adaptors.

André Veillette1.   

Abstract

The signalling lymphocytic activation molecule (SLAM) family of receptors is expressed by a wide range of immune cells. Through their cytoplasmic domain, SLAM family receptors associate with SLAM-associated protein (SAP)-related molecules, a group of cytoplasmic adaptors composed almost exclusively of an SRC homology 2 domain. SAP, the prototype of the SAP family, is mutated in a human immunodeficiency named X-linked lymphoproliferative (XLP) disease. Recent observations indicate that SLAM family receptors, in association with SAP family adaptors, have crucial roles during normal immune reactions in innate and adaptive immune cells. The latest progress in this field is reviewed here.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16493427     DOI: 10.1038/nri1761

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  77 in total

1.  Fine-tuning of CD8(+) T-cell effector functions by targeting the 2B4-CD48 interaction.

Authors:  Anna Lissina; David R Ambrozak; Kristin L Boswell; Wenjing Yang; Eli Boritz; Yoshiyuki Wakabayashi; Maria C Iglesias; Masao Hashimoto; Masafumi Takiguchi; Elias Haddad; Daniel C Douek; Jun Zhu; Richard A Koup; Takuya Yamamoto; Victor Appay
Journal:  Immunol Cell Biol       Date:  2016-02-10       Impact factor: 5.126

Review 2.  Sequence, structure, function, immunity: structural genomics of costimulation.

Authors:  Kausik Chattopadhyay; Eszter Lazar-Molnar; Qingrong Yan; Rotem Rubinstein; Chenyang Zhan; Vladimir Vigdorovich; Udupi A Ramagopal; Jeffrey Bonanno; Stanley G Nathenson; Steven C Almo
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

3.  Manipulation of EAT-2 expression promotes induction of multiple beneficial regulatory and effector functions of the human innate immune system as a novel immunomodulatory strategy.

Authors:  Yasser A Aldhamen; Sergey S Seregin; Charles F Aylsworth; Sarah Godbehere; Andrea Amalfitano
Journal:  Int Immunol       Date:  2013-12-27       Impact factor: 4.823

4.  Weak cis and trans Interactions of the Hemagglutinin with Receptors Trigger Fusion Proteins of Neuropathogenic Measles Virus Isolates.

Authors:  Yuta Shirogane; Takao Hashiguchi; Yusuke Yanagi
Journal:  J Virol       Date:  2020-01-06       Impact factor: 5.103

Review 5.  CS1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma.

Authors:  Joseph D Malaer; Porunelloor A Mathew
Journal:  Am J Cancer Res       Date:  2017-08-01       Impact factor: 6.166

Review 6.  SLAM receptors and SAP influence lymphocyte interactions, development and function.

Authors:  Pamela L Schwartzberg; Kristen L Mueller; Hai Qi; Jennifer L Cannons
Journal:  Nat Rev Immunol       Date:  2009-01       Impact factor: 53.106

Review 7.  Tec kinases regulate T-lymphocyte development and function: new insights into the roles of Itk and Rlk/Txk.

Authors:  Julie A Readinger; Kristen L Mueller; Ana M Venegas; Reiko Horai; Pamela L Schwartzberg
Journal:  Immunol Rev       Date:  2009-03       Impact factor: 12.988

8.  Measles virus breaks through epithelial cell barriers to achieve transmission.

Authors:  Makoto Takeda
Journal:  J Clin Invest       Date:  2008-07       Impact factor: 14.808

9.  T Cells Regulate Peripheral Naive Mature B Cell Survival by Cell-Cell Contact Mediated through SLAMF6 and SAP.

Authors:  Lihi Radomir; Sivan Cohen; Matthias P Kramer; Eszter Bakos; Hadas Lewinsky; Avital Barak; Ziv Porat; Richard Bucala; Polina Stepensky; Shirly Becker-Herman; Idit Shachar
Journal:  J Immunol       Date:  2017-09-13       Impact factor: 5.422

10.  SLAMF1 regulation of chemotaxis and autophagy determines CLL patient response.

Authors:  Cinzia Bologna; Roberta Buonincontri; Sara Serra; Tiziana Vaisitti; Valentina Audrito; Davide Brusa; Andrea Pagnani; Marta Coscia; Giovanni D'Arena; Elisabetta Mereu; Roberto Piva; Richard R Furman; Davide Rossi; Gianluca Gaidano; Cox Terhorst; Silvia Deaglio
Journal:  J Clin Invest       Date:  2015-11-30       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.